FLT3 receptor antagonists
US10065937B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 30, 2015 |
| Grant date | Sep 4, 2018 |
| Priority date | — |
| Expiry date | Jul 30, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D263/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.